| Name | Title | Contact Details |
|---|
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead`s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.
JSR Life Sciences is a business unit of JSR Corporation, a global company built on more than 50 years of performance material expertise and it began research in the life sciences field more than 30 years ago. We are continually developing highly functional materials and products to meet the current and future needs of the growing biotechnology industry. Using a variety of integrated, leading-edge technologies, JSR Life Sciences provides materials that contribute to the manufacturing process of biopharmaceuticals, life science research applications, in vitro diagnostics and medical devices. JSR Life Sciences has offices, laboratories and manufacturing facilities in Tokyo and Tsukuba (JP), Sunnyvale (CA, USA), Leuven (BE) and Beijng (CN). We are a part of the JSR Corporation, an international company employing over 6’000 people worldwide and being a leading materials supplier in a variety of technology driven markets. JSR Corporation`s global network is headquartered in Tokyo (Japan) and has factories and offices all over the world. As a research-oriented organization, JSR Corporation pursues close collaborations with leading innovators in a number of industries that are key to the present and future welfare of human society: life sciences, elastomers, electronic materials, energy storage, display materials and optical materials.
Vibalogics is a CDMO offering process development, manufacturing, testing, and fill-finish services to innovators developing revolutionary virotherapy products.
Inari embraces diversity in every aspect of our business to drive innovation and help build a new food system. Our technology matches the complexity of nature to transform seed using predictive design and multiplex gene editing – unlocking the full potential through our SEEDesign™ platform. The result is step-change products that lead to more productive acres and a more sustainable future for the food system.
Quantapore`s novel, high throughput, massively parallel sequencer will allow rapid, affordable and sensitive sequencing of entire genomes. This desktop system will address the need for efficient sequencing. Revenues will be garnered by seeding units into customer facilities, and then by the sale of consumable cartridges; providing rapid growth as the installed base and customer utilization increases.